• 2022年6月21-23日
  • 上海新国际博览中心N5馆

Brian Hosung Min



How innovative business models accelerate drug development

Brian Hosung Min

Brian Hosung Min



Dr. Min held a Ph.D. in Molecular Biology from the University of California at Los Angeles in 1997. Dr. Min’s expertise includes biologics development from discovery to manufacturing as well as strategic planning and business development. 


From 2008 to 2018, he worked as Senior Vice President of Process Team at Samsung Bioepis Co., Ltd., mainly responsible for the development, manufacturing and registration of antibody drugs and antibody biosimilars. He was in charge of quite a few biosimilar projects, 4 of which are now on the market in the US, Europe and South Korea, 2 are at Phase III clinical trials and 2 at Phase I clinical trials. From 1997 to 2007, Dr. Min worked as principal scientist at Amgen, mainly responsible for biologics discovery and development. At the time, he also led the projects of many biologics that are currently on the market or under clinical trials.